|
|
Post by awesomo on Nov 18, 2019 22:21:26 GMT -5
So Cipla doesn’t care, the rejection occurred in April and they are still in the planning phase. “Expected in the new year”, nice timeframe there!
|
|
|
|
Post by mnkdfann on Nov 18, 2019 23:30:28 GMT -5
So Cipla doesn’t care, the rejection occurred in April and they are still in the planning phase. “Expected in the new year”, nice timeframe there! From April until mid-October, Cipla had bigger worries. Over that period its share price lost about 30% (to 52 week lows), and the US FDA was on its back about failures at one of its plants. |
|
|
|
Post by brotherm1 on Jan 15, 2020 12:27:32 GMT -5
I’m thinking we have under $60M end of Sept. I’m guessing we are burning about $8M monthly. Not counting on $1.60 warrants being excercised in December. Anyone recall how much cash we need to keep in escrow ? Will we be borrowing or diluting with shares? . Looks like we had around $50mm cash end of September less - what I recall if correct - is 15mm we need in escrow. Thus $35mm. Then plus 12.5mm in November from UTHR 2nd milestone = 47.5mm. Less approx cash burn of 8mm per month leaves us with an estimated cash balance of $15.5mm end of this month of January. I don’t know what the $5mm raised from the sold shares in December was for so I’m not counting that. |
|
|
|
Post by sportsrancho on Jan 15, 2020 13:01:33 GMT -5
I’m thinking we have under $60M end of Sept. I’m guessing we are burning about $8M monthly. Not counting on $1.60 warrants being excercised in December. Anyone recall how much cash we need to keep in escrow ? Will we be borrowing or diluting with shares? . Looks like we had around $50mm cash end of September less - what I recall if correct - is 15mm we need in escrow. Thus $35mm. Then plus 12.5mm in November from UTHR 2nd milestone = 47.5mm. Less approx cash burn of 8mm per month leaves us with an estimated cash balance of $15.5mm end of this month of January. I don’t know what the $5mm raised from the sold shares in December was for so I’m not counting that. Was it for Deerfield? |
|
|
|
Post by bthomas55ep on Jan 15, 2020 14:45:50 GMT -5
. Looks like we had around $50mm cash end of September less - what I recall if correct - is 15mm we need in escrow. Thus $35mm. Then plus 12.5mm in November from UTHR 2nd milestone = 47.5mm. Less approx cash burn of 8mm per month leaves us with an estimated cash balance of $15.5mm end of this month of January. I don’t know what the $5mm raised from the sold shares in December was for so I’m not counting that. Was it for Deerfield? I think he means the $5M on the sale of the shares for the partial Warrant repricing. That raised another $5M. If so, his estimate would then be $20.5M left in cash at the end of the month. I think. |
|
|
|
Post by agedhippie on Jan 15, 2020 23:08:54 GMT -5
Here is what’s very likely: Q3 sales revenue > 7M Q4 - 12.5M milestone from UTHR Q4 sales revenue > 8M H1 2020 - 12.5M milestone from UTHR H2 2020 - 12.5M milestone from UTHR Flexibility from either warrants or drawing from mid cap facility 10M. Minimum + 62M in next 18 months. Brazil revenue and other business developments will complete the picture to CFBE. That's the revenue, but what are the costs over that period? |
|
|
|
Post by awesomo on Jan 15, 2020 23:31:31 GMT -5
Here is what’s very likely: Q3 sales revenue > 7M Q4 - 12.5M milestone from UTHR Q4 sales revenue > 8M H1 2020 - 12.5M milestone from UTHR H2 2020 - 12.5M milestone from UTHR Flexibility from either warrants or drawing from mid cap facility 10M. Minimum + 62M in next 18 months. Brazil revenue and other business developments will complete the picture to CFBE. That's the revenue, but what are the costs over that period? Average expense over the last year was a little over $25M per quarter, so $150M for 18 months. Not even close to CFBE. |
|
|
|
Post by mytakeonit on Jan 15, 2020 23:38:04 GMT -5
I guess everyone is guessing because they can't wait till the year end CC to get the real numbers? To all I say buy/acquire all the shares you can at these cheap prices.
But, that's mytakeonit
|
|
|
|
Post by pat on Jan 16, 2020 7:07:53 GMT -5
This stock seems to mirror the countries political environment. Two competing narratives, each wildly opposite and at odds with one another. This forum is like the cable news networks. Very little ‘new news’ each day with most time spent rehashing arguments made previous. Stalwart defenders in each camp. Boredom, frustration, a bit of humor.
Well, I’d say this is the year either side is proven right - and I’m not talking about the election.
|
|
|
|
Post by prcgorman2 on Jan 16, 2020 7:11:35 GMT -5
Really? 2020? Hmmm. We have different horizons. We talked about revenue. We didn’t talk about extending the runway. It is possible. And there is always the unknown business deal that can materialize. Is it a good assmption that UTHR and RLS and Brazil and China are all that will happen?
|
|
|
|
Post by pat on Jan 16, 2020 9:34:32 GMT -5
Don’t get me wrong. The short position is holding down the share price and choking access to $$ that would allow us to fuel our growth. So who knows when we’ll see significant momentum build. I’m just betting it’s this year.
I think that’s what you’re getting at...
|
|
|
|
Post by boca1girl on Jan 16, 2020 9:51:04 GMT -5
Sanofi's former CEO, Brandicort, also said in a video/transcript I saw on Proboards, that Afrezza wouldn’t be commercially viable until 2020.
I don’t remember any reasoning given, just the statement. Must be something magical about 2020.
|
|
|
|
Post by mango on Jan 16, 2020 9:56:17 GMT -5
Sanofi's former CEO, Brandicort, also said in a video/transcript I saw on Proboards, that Afrezza wouldn’t be commercially viable until 2020. I don’t remember any reasoning given, just the statement. Must be something magical about 2020. If you remember where it is will you please post the link? 🙂 |
|
|
|
Post by mnkdfann on Jan 16, 2020 10:07:44 GMT -5
Sanofi's former CEO, Brandicort, also said in a video/transcript I saw on Proboards, that Afrezza wouldn’t be commercially viable until 2020. I don’t remember any reasoning given, just the statement. Must be something magical about 2020. Was this back when Sanofi was still involved, and actively trying to make Afrezza commercially viable? (I suppose it almost must have been; why else would he comment.) |
|
|
|
Post by MnkdWASmyRtrmntPlan on Jan 16, 2020 11:01:22 GMT -5
Sanofi's former CEO, Brandicort, also said in a video/transcript I saw on Proboards, that Afrezza wouldn’t be commercially viable until 2020. I don’t remember any reasoning given, just the statement. Must be something magical about 2020. If you remember where it is will you please post the link? 🙂 I looked for, but could not find any such quote from Brandicort. While not a direct quote by Brandicourt, this article lends credence that he stated that it was not viable. But, I don't know where the 2020 part came from. Viehbacher's team did Brandicourt and the board a big favor when they set up the partnership. Sanofi can give rights to Afrezza back to MannKind after January 2016 with 90 days notice if the company "determines in good faith that the commercialization of Afrezza is no longer economically viable in the United States," according to an SEC document filed by MannKind. From here: www.fool.com/investing/general/2015/02/24/mannkind-corporations-new-boss-no-the-other-one.aspx |
|
